William Ricke, PhD

Position title: Professor, O’Brien Center Director, UWMF-Professor of Urologic Research Director of Research

Email: rickew@urology.wisc.edu

Phone: 608-265-3202

Wisconsin Institutes for Medical Research
1111 Highland Avenue

Lab Website
Ricke Lab
William Ricke

Research Interests

Understanding the role of endocrine disrupting chemicals, phytonutrients, and stromal-epithelial interactions in the development or treatment of urologic diseases (e.g. benign prostatic hyperplasia and prostate cancer).

–Evaluation of bisphenol-A in obstructive voiding disorders (RC2 grant, NIEHS)
–Role of phthalates and bisphenols in prostate cancer progression
–Evaluation of bisphenol-A in urinary tract development (U01 grant, NIEHS)
–Role of dioxin in urinary dysfunction (METC pilot grant, NIEHS)

Selected Publications

  • Theberge AB, Yu J, Young EW, Ricke WA, Bushman W, Beebe DJ. Microfluidic multiculture assay to analyze biomolecular signaling in angiogenesis.Anal. Chem. 2015 Mar 17; 87(6):3239-46.
  • Moses MA, Henry EC, Ricke WA, Gasiewicz TA. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Cancer Prev Res (Phila) 2015 Mar; 8(3):249-57.
  • Bauman TM, Vezina CM, Huang W, Marker PC, Peterson RE, Ricke WA. Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue. Am J Clin Exp Urol 2014; 2(4):313-22.
  • Keil KP, Abler LL, Altmann HM, Bushman W, Marker PC, Li L, Ricke WA, Bjorling DE, Vezina CM. Influence of animal husbandry practices on void spot assay outcomes in C57BL/6J male mice. Neurourol. Urodyn. 2014 Nov 12.
  • Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, Ricke WA.Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS ONE 2014; 9(10):e109102.
  • Nicholson TM, Moses MA, Uchtmann KS, Keil KP, Bjorling DE, Vezina CM, Wood RW, Ricke WA. Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J. Urol. 2015 Feb; 193(2):722-9.
  • Peretz J, Vrooman L, Ricke WA, Hunt PA, Ehrlich S, Hauser R, Padmanabhan V, Taylor HS, Swan SH, VandeVoort CA, Flaws JA. Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013. Environ. Health Perspect. 2014 Aug; 122(8):775-86.
  • Bauman TM, Sehgal PD, Johnson KA, Pier T, Bruskewitz RC, Ricke WA, Huang W.Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate 2014 Jun; 74(9):923-32.
  • Lewis SR, Hedman CJ, Ziegler T, Ricke WA, Jorgensen JS. Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology 2014 Feb; 155(2):358-69.
  • Nicholson TM, Uchtmann KS, Valdez CD, Theberge AB, Miralem T, Ricke WA.Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia. J Vis Exp 2013; (78):.